KUALA LUMPUR: Crown Bioscience Inc has launched a new tumour organoid drug development platform with potential to significantly improve the predictivity and speed of preclinical drug discovery.
The initial phase of the platform launch features the first commercially available 3D in vitro PDX-derived organoid (PDXO) models, generated from the company’s uniquely-characterised library of over 2,500 patient-derived xenograft (PDX) models.
Further benefits of patient-relevant PDXO models include preserving the genomic, morphological and pathophysiological identity of their parental PDX tumours.
PDXOs are biologically equivalent to highly predictive in vivo PDX models, both being cancer stem cell driven disease models.
PDXOs bring the added benefits of speed and scalability inherent to in vitro systems which are ideal for high-throughput, large-scale screens and simultaneous testing of multiple combination strategies.
These 3D in vitro models have been developed using best-in-class Hubrecht Organoid Technology (HUB) protocols, originating from the Clevers lab, guaranteeing robustness and proven translatability.
CrownBio has an exclusive licence from HUB to provide preclinical oncology drug development and validation services using HUB’s Organoid Technology.
The initial launch of PDXO models includes more than 10 cancer types. Phase 2 of the platform will see HUB patient-derived organoids available exclusively from CrownBio in first quarter next year. – Bernama
